Prime Medicine CSO departs, reveals new funding; FDA lifts partial hold on Kezar drugnews2025-07-16T14:36:41+00:00July 16th, 2025|Endpoints News|
Otsuka buys immunology drugs; JCR, Acumen team up on Alzheimer’s programnews2025-07-15T14:21:06+00:00July 15th, 2025|Endpoints News|
Boehringer, LEO ink deal for IL-36 drug; Bayer’s Kerendia gets another indicationnews2025-07-14T14:48:47+00:00July 14th, 2025|Endpoints News|
Manufacturing layoffs at Pacira; Oak Hill Bio’s Phase 1 Angelman datanews2025-07-11T15:07:30+00:00July 11th, 2025|Endpoints News|
AstraZeneca hands over opioid addiction pill to Eolas; TandemAI, Perpetual Medicines mergenews2025-07-10T14:45:33+00:00July 10th, 2025|Endpoints News|
Novartis’ brain delivery platform option deal worth up to $175M; Neumora’s next stepsnews2025-07-09T14:54:34+00:00July 9th, 2025|Endpoints News|
Recursion takes full rights to rare genetic disorder drug; CStone out-licenses cancer drug in Europenews2025-07-08T14:26:04+00:00July 8th, 2025|Endpoints News|
Denali’s Hunter syndrome therapy gets priority review; LENZ inks Canada dealnews2025-07-07T14:46:50+00:00July 7th, 2025|Endpoints News|
Cloudbreak’s shares stumble in Hong Kong debut; Sinovac squares off against activistnews2025-07-03T14:27:11+00:00July 3rd, 2025|Endpoints News|
Organon stops work on drug once viewed as ‘game-changing’; NextPoint culls an assetnews2025-07-02T14:34:02+00:00July 2nd, 2025|Endpoints News|
